[1] ind JS, Smit EF, Grǜnberg K, et al.Fatal interstitial lung disease after erlotinib for non-small cell lung cancer[J].J Thorac Oncol, 2008, 3(9):1050-1053.
[2] Liu V, White DA, ZakowskiMF, et al.Pulmonary toxicity associated with erlotinib[J].Chest, 2007, 132(3): 1042-1044.
[3] Makris D, Scherpereel A, Copin MC, et al.Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer[J].BMC Cancer, 2007, 7:150-153.
[4] Costa DB, Kobayashi S, Tenen DG, et al.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers[J].Lung Cancer, 2007, 58(1):95-103.
[5] Kubota K, Nishiwaki Y, Tamura T, et al.Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer:a phase II study [J].J Thorac Oncol, 2008, 3(12):1439-1445.
[6] Kato T, Nishio K.Clinical aspects of epidermal growth factor receptor inhibitors:Benefit and risk[J].Respirology, 2006, 11(6):693-698.
[7] Aoe K, Hiraki A, Murakami T, et al.Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy[J].Anticancer Res, 2005, 25(1B):415-418.
[8] Tammaro KA, Baldwin PD, Lundberg AS.Interstitial lung disease following erlotinib (Tarceva)in a patient who previously tolerated gefitinib (Iressa)[J].ASJ Oncol Pharm Pract, 2005, 11(3):127-130.
[9] Cohen MH, Johnson JR, Chen YF, et al.FDA drug approval summary:erlotinib (Tarceva)tablets[J].The Oncologist, 2005, 10(7):461-466.
[10] Camus P, Kudoh S, Ebina M.Interstitial lung disease associated with drug therapy [J].Br J Cancer, 2004, 91 (Suppl 2):S18-S23. |
